Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLONPREP
2017-002542-72Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2018
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ornidazole, gentamicin and sennosid A + sennosid B in surgical site infection (SSI) and bacterial disease (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: 30-day postoperative surgical site infection rate. Started Mar 2018; status: active.
02
Drugs
ornidazolegentamicinsennosid A + sennosid B
03
Conditions
surgical site infection (SSI)bacterial disease
Beyond the preview
Go deeper on 2017-002542-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002542-72.